InflaRx
Price & Volume
Stats
See more52W Range | $1.16-$2.81 |
Market Cap | $141.9M |
Shares Short | 216,542 |
Financials
See moreRevenue (12 Mos) | $105,483 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$1.01 |
News
See moreYahoo Finance • last year
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
Yahoo Finance • last year
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
Yahoo Finance • last year
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
Yahoo Finance • 2 years ago
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
About
CEO | Dr. Niels C. Riedemann M.D., Ph.D. |
Address | Winzerlaer Str. 2, Jena, Germany, 07745 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 62 |
